Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
HIV, HCV and TB Pipeline Report

Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

Published
21 July 2014
From
Treatment Action Group & i-Base
J&J beats forecasts, helped by new hepatitis C drug

Johnson & Johnson (JNJ.N) reported sharply better-than-expected quarterly revenue and earnings, fueled by strong sales of newer prescription drugs, including its Olysio treatment for hepatitis C.

Published
16 July 2014
From
Reuters
US govt demands more pricing info on Gilead HCV pill

The cost of Gilead Sciences’ hepatitis C pill Sovaldi is once again under the spotlight with the US Senate Finance Committee requesting detailed pricing information.

Published
15 July 2014
From
Pharma Times
EU nations join forces against 'exorbitant' hepatitis C drug: France

France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

Published
10 July 2014
From
Medical Xpress
US: Studies look at hepatitis C care cascade and healthcare utilization

Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE.

Published
08 July 2014
From
HIVandHepatitis.com
Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor.

Published
08 July 2014
From
Bristol-Myers Squibb press release
Patients coinfected with HIV, HCV showed spontaneous HCV clearance during ART

Three patients coinfected with hepatitis C virus and HIV spontaneously became negative for HCV RNA while undergoing antiretroviral therapy, and all had the IL28B CC genotype in a recent study.

Published
07 July 2014
From
Healio
Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza® (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Published
30 June 2014
From
Bristol-Myers Squibb press release
Fighting for their lives: Economist Intelligence Unit report finds patient groups lead global efforts to address hepatitis C

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide.

Published
25 June 2014
From
Janssen press release
HCV drug out of the running

The German pharmaceutical giant Boehringer Ingelheim is stopping development of faldaprevir, its hepatitis C virus (HCV) drug.

Published
23 June 2014
From
MedPage Today
← First12345...72Next →

Filter by country